RESUMEN
BACKGROUND: Primary intracranial malignant melanoma (PIMM) is rare, and its prognosis is very poor. It is not clear what systematic treatment strategy can achieve long-term survival. This case study attempted to identify the optimal strategy for long-term survival outcomes by reviewing the PIMM patient with the longest survival following comprehensive treatment and by reviewing the related literature. CASE SUMMARY: The patient is a 47-year-old Chinese man who suffered from dizziness and gait disturbance. He underwent surgery for right cerebellum melanoma and was subsequently diagnosed by pathology in June 2000. After the surgery, the patient received three cycles of chemotherapy but relapsed locally within 4 mo. Following the second surgery for total tumor resection, the patient received an injection of Newcastle disease virus-modified tumor vaccine, interferon, and ß-elemene treatment. The patient was tumor-free with a normal life for 21 years before the onset of the recurrence of melanoma without any symptoms in July 2021. A third gross-total resection with adjuvant radiotherapy and temozolomide therapy was performed. Brain magnetic resonance imaging showed no residual tumor or recurrence 3 mo after the 3rd operation, and the patient recovered well without neurological dysfunction until the last follow-up in June 2022, which was 22 years following the initial treatment. CONCLUSION: It is important for patients with PIMM to receive comprehensive treatment to enable the application of the most appropriate treatment strategies. Long-term survival is not impossible in patients with these malignancies.
RESUMEN
Purpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal prognosis and the definitive treatment strategy has not yet been established. This study aimed to assess the efficacy and safety of apatinib in recurrent/progressive GBM patients. Materials and methods: The clinical data of 19 recurrent/progressive GBM patients who received apatinib treatment from November 2015 to December 2019 at Sun Yat-sen University Cancer Center were collected retrospectively in this study. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs) were reviewed and assessed. Results: The overall ORR was 52.6%, and the DCR was 73.7%. Median PFS and OS were 5.1 and 10.4 months, respectively. The 6-month PFS and OS rates were 38.9% and 68.4%, respectively. The 12-month PFS and OS rates were 16.7% and 36.8%, respectively. The treatment-related toxicities were generally well-tolerated. The most common grade 3/4 AEs were hand-foot syndrome (36.8%) and hypertension (21.1%). Conclusion: Our study showed that apatinib therapy provided a better salvaging option for recurrent/progressive GBM patients and the toxicity was manageable.
RESUMEN
Background: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) antibody that has shown preclinical and clinical anticancer activity in cerebral glioblastoma multiforme (GBM). We conducted a phase II, single-arm, multicenter clinical trial to evaluate the benefit of adding nimotuzumab to current standard chemo-radiotherapy for patients with GBM with positive EGFR expression. Methods: Newly diagnosed patients with histologically proven single supratentorial GBM and epidermal growth factor receptor (EGFR) positive expressions were recruited. All patients were treated with nimotuzumab, administered once a week intravenously for 6 weeks in addition to radiotherapy with concomitant and adjuvant temozolomide after surgery. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary objectives included objective response rate (ORR) and toxicity. Results: A total of 39 patients were enrolled and 36 patients were evaluated for efficacy. The ORR at the end of RT was 72.2%. Median OS and PFS were 24.5 and 11.9 months. The 1-year OS and PFS rates were 83.3% and 49.3%. The 2-year OS and PFS rates were 51.1% and 29.0%. O (6)-methylquanine DNA methyl-tranferase (MGMT) expression is known to affect the efficacy of chemotherapy and status of its expression is examined. No significant correlation between treatment outcomes and MGMT status was found. Most frequent treatment-related toxicities were mild to moderate and included constipation, anorexia, fatigue, nausea, vomiting, and leucopenia. Conclusions: Our study show that nimotuzumab in addition to standard treatment is well tolerable and has increased survival in newly diagnosed GBM patients with EGFR positive expression.
RESUMEN
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is revolutionizing the management of brain metastases (BMs). This study was to explore the value of upfront cranial radiotherapy (RT) in EGFR-mutated non-small cell lung cancer (NSCLC) with BMs compared with EGFR-TKIs alone. Methods: We searched all topic-related comparative articles in public databases (MEDLINE, EMBASE, Cochrane Library, and Web of Science) and conference proceedings. Outcomes of interest were intracranial objective response rate (ORR), overall survival (OS), and intracranial progression-free survival (PFS). Statistical analyses were calculated using Review Manager 5.3 software. Results: Thirteen comparative studies that included a total of 1,456 patients were eligible. Upfront brain RT had significantly higher OS (HR = 0.78, 95% CI = 0.65-0.93, P = 0.005) than EGFR-TKI alone. Upfront RT plus TKI had superior OS (HR = 0.71, 95% CI = 0.58-0.86, P = 0.0005) and intracranial PFS (HR = 0.69, 95% CI = 0.49-0.99, P = 0.04). The pooled data favored upfront whole brain RT (WBRT) plus TKI in terms of intracranial PFS (HR = 0.64, 95% CI = 0.48-0.85, P = 0.002) and OS (HR = 0.75, 95% CI = 0.57-1, P = 0.05). Upfront stereotactic radiosurgery (SRS) was associated with better OS (HR = 0.37, 95% CI = 0.26-0.54, P < 0.00001). Similar results were observed when analysis was restricted to the use of erlotinib or geftinib. Conclusions: The upfront use of brain RT seemed critical, especially for SRS. Upfront administration of upfront WBRT plus EGFR-TKI had better survival outcomes and seemed superior to EGFR-TKI alone.
RESUMEN
MicroRNAs (miRNAs) are short noncoding RNAs that play critical roles in human malignancies and can be used as biomarkers for cancer. Until now, a number of biomarkers for prognosis of glioblastoma (GBM) have been reported in tumor tissues but only a few biomarkers in circulating fluid. Using a custom microarray, we previously identified 19 differentially expressed miRNAs in serum of patients with GBM. In this study, we investigated whether 3 of the 19 miRNAs in serum could be used as prognostic biomarkers for patients with GBM. We first validated the serum levels of 3 candidate miRNAs in an independent cohort of 24 GBM patients and 12 healthy volunteers by real-time quantitative reverse transcription PCR (qRT-PCR), and then evaluated the prognostic value of these miRNAs in a total of 36 GBM patients. The results show that the serum levels of the 3 miRNAs (miR-451a, miR-485-3p and miR-4298) determined by qRT-PCR are significantly different between 24 GBM patients and 12 healthy volunteers (all P <0.05) and are in concordance with the results of microarray analysis. High serum level of miR-451a is correlated with positive tumor O(6)-methylguanine-DNA methyltransferase (MGMT) expression (P = 0.040). Survival analysis showed that low serum miR-485-3p level is associated with poor progression-free survival (PFS) (P < 0.004) and overall survival (OS) (P < 0.023). Furthermore, univariate and multivariate Cox analyses demonstrated that that serum miR-485-3p expression is a significant independent prognostic factor for PFS and OS in GBM patients. In conclusion, serum miR-485-3p level is reduced and might be a potential prognostic biomarker in GBM patients.
Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias Encefálicas/mortalidad , Glioblastoma/mortalidad , MicroARNs/genética , Adolescente , Adulto , Anciano , Biomarcadores de Tumor/sangre , Neoplasias Encefálicas/sangre , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Estudios de Casos y Controles , Terapia Combinada , Metilasas de Modificación del ADN/sangre , Enzimas Reparadoras del ADN/sangre , Femenino , Estudios de Seguimiento , Regulación Neoplásica de la Expresión Génica , Glioblastoma/sangre , Glioblastoma/genética , Glioblastoma/patología , Humanos , Masculino , MicroARNs/sangre , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Reacción en Cadena en Tiempo Real de la Polimerasa , Tasa de Supervivencia , Proteínas Supresoras de Tumor/sangre , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVE: Primary intracranial germ cell tumors (GCTs) are a class of heterogeneous tumors. Surgery can quickly relieve tumor compression and provide histological diagnosis. It is very difficult to treat some patients who are unable to be pathologically diagnosed. We aimed to analyze clinically diagnosed GCTs patients. METHODS: Patients clinically diagnosed as primary intracranial GCTs were included in this study. RESULTS: From 2002 to 2015, 42 patients clinically diagnosed with primary intracranial GCTs received chemotherapy and/or radiotherapy. Patients were assigned to diagnostic chemotherapy group (25 cases), diagnostic radiotherapy group (5 cases) and gamma knife radiosurgery group (12 cases) based on their initial anti-tumor therapy. The 5-year survival rates were 85.8%, 75.0% and 63.6%, respectively. There were no statistically significant difference (p value = 0.44). Patients were assigned to the group (30 cases) with secretory tumors and the group (12 cases) with non-secretory tumors based on their levels of tumor makers. The 5- year survival rates were 80.7% and 68.6%, respectively. There were no statistically significant difference (p value = 0.49).The major adverse reactions were grade III - IV bone marrow suppression with an incidence of 35.2% and grade II- III nausea/vomiting with an incidence of 45.8%. CONCLUSION: Surgical removal of tumor or biopsy is recognized as the most accurate method to determine the pathological property of tumor. But for some patients who can not be pathologically diagnosed, they can receive comprehensive treatments such as chemotherapy combined with radiotherapy, and some of them can still have good responses.
Asunto(s)
Neoplasias Encefálicas/diagnóstico , Células Madre Neoplásicas/patología , Síndromes Paraneoplásicos Endocrinos/diagnóstico , Adolescente , Adulto , Enfermedades de la Médula Ósea/etiología , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/terapia , Niño , Terapia Combinada , Quimioterapia , Femenino , Humanos , Masculino , Síndromes Paraneoplásicos Endocrinos/mortalidad , Síndromes Paraneoplásicos Endocrinos/patología , Síndromes Paraneoplásicos Endocrinos/terapia , Náusea y Vómito Posoperatorios/etiología , Radiocirugia/efectos adversos , Radioterapia/efectos adversos , Análisis de Supervivencia , Adulto Joven , alfa-Fetoproteínas/metabolismoRESUMEN
BACKGROUND AND OBJECTIVE: X-ray stereotactic radiotherapy (SRT) is one of the effective treatments for brain metastases (BM). This study was to evaluate the efficacy of SRT on BM, and investigate prognostic factors. METHODS: Between July 1999 and December 2004, a total of 122 intracranial lesions in 78 patients with BM were treated using SRT in our Center. Forty-nine patients had a solitary lesion and 29 had multiple (2-6) lesions. The median SRT dose was 15 Gy (11-24 Gy) in single fraction for 38 lesions, and 24 Gy (11-40 Gy) in 2-6 fractions for 84 lesions. SRT was combined with whole brain radiotherapy (WBRT) of 30-40 Gy for 39 patients. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Univariate and multivariate analyses were performed by the log-rank test and Cox model, respectively. RESULTS: The median survival time was 12.9 months (1.7-77.4 months). The 1-year intracranial PFS rate was 87.4%. The 1-and 2-year OS rates were 53.9% and 25.8%, respectively. Univariate analysis showed that the 1-year OS rates were higher in the patients with pretreatment KPS of >/= 70, extracranial lesions controlled, or SRT combined with WBRT than in those with KPS of < 70 (60.7% vs. 29.4%, P = 0.002), extracranial lesions uncontrolled (69% vs. 44.9%, P = 0.005), or SRT alone (64.1% vs. 43.4%, P = 0.03). The benefit of treating with WBRT in combination was mainly achieved in the patients with extracranial lesions controlled or with more than one intracranial lesion. Multivariate analysis showed that KPS score and status of extracranial lesions were independent prognostic factors for OS. CONCLUSIONS: SRT is an effective and safe modality for BM. SRT combined with WBRT may prolong the survival time of the patients with extracranial lesions controlled or multiple intracranial lesions. Independent prognostic factors for OS are KPS score and status of extracranial lesions.
Asunto(s)
Neoplasias Encefálicas/cirugía , Irradiación Craneana/métodos , Estado de Ejecución de Karnofsky , Neoplasias Glandulares y Epiteliales/cirugía , Radiocirugia/métodos , Adulto , Anciano , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/secundario , Neoplasias de la Mama/patología , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Neoplasias Glandulares y Epiteliales/radioterapia , Neoplasias Glandulares y Epiteliales/secundario , Modelos de Riesgos Proporcionales , Dosificación Radioterapéutica , Tasa de SupervivenciaRESUMEN
Poly(ethylene glycol) (PEG), an environment-friendly reaction medium, has been adopted to accelerate the dehydrochlorination of poly(vinyl chloride) (PVC). Experimental results demonstrated that at 210 degrees C for 1h the dechlorination degree was as high as 74.2% for PVC/PEG, while for PVC only 50.0%. Moreover, from thermogravimetric analysis, it was found that for PVC/PEG the decomposition of PVC corresponding to the dehydrochlorination stage shifted to lower temperatures compared with that of pure PVC, suggesting some interactions exist between PEG and PVC that caused the faster dehydrochlorination rate. In addition, during this process, no waste byproducts such as KCl have been produced, and satisfactory recyclability of PEG (10 cycles) has been obtained.
Asunto(s)
Cloro/aislamiento & purificación , Cloruro de Polivinilo/química , Cloro/química , PolietilenglicolesRESUMEN
PURPOSE: Local recurrence remains one of the major causes of failure in nasopharyngeal carcinoma (NPC). Stereotactic radiosurgery and fractionated stereotactic radiation therapy (FSRT) have recently evolved as a salvage option of NPC. This study was conducted to review the treatment outcome after FSRT for NPC. METHODS AND MATERIALS: Between September 1999 and December 2005, 90 patients with persistent (Group 1: n = 34, relapse within 6 months of RT) or recurrent (Group 2: n = 56, relapse beyond 6 months) NPC received FSRT using multiple noncoplanar arcs of 8-MV photon to the target. Median FSRT dose was 18 Gy in three fractions (Group 1) or 48 Gy in six fractions (Group 2). Median follow-up was 20.3 months. RESULTS: Complete response rate after FSRT was 66% for Group 1 and 63% for Group 2. One-, 2-, and 3-year disease-specific survival (DSS) and progression-free survival (PFS) rates for all patients were 82.6%, 74.8%, 57.5%, and 72.9%, 60.4%, 54.5%, respectively. Three-year local failure-free survival, DSS, and PFS rates were 89.4%, 80.7%, and 72.3% for Group 1, and 75.1%, 45.9%, and 42.9% for Group 2, respectively. Multivariate analysis showed that recurrent disease and large tumor volume were independent factors that predicted poorer DSS and PFS. Seventeen patients developed late complications, including 2 with fatal hemorrhage. CONCLUSIONS: Our results indicate that FSRT is effective for patients with persistent and recurrent NPC. Compared with reported results of radiosurgery, FSRT provides satisfactory tumor control and survival with a lower risk of complications and it may be a better treatment for local failures of NPC.
Asunto(s)
Neoplasias Nasofaríngeas/cirugía , Recurrencia Local de Neoplasia/cirugía , Radiocirugia/métodos , Terapia Recuperativa/métodos , Adolescente , Adulto , Anciano , Causas de Muerte , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Neoplasias Nasofaríngeas/mortalidad , Neoplasias Nasofaríngeas/radioterapia , Recurrencia Local de Neoplasia/mortalidad , Radiocirugia/efectos adversos , Terapia Recuperativa/efectos adversos , Resultado del TratamientoRESUMEN
BACKGROUND & OBJECTIVE: There are only a few traditional treatment methods for lung metastasis, and the therapeutic effectiveness is not satisfactory. X-ray stereotactic radiotherapy (SRT) is developed as a new treatment option of lung metastasis in recent years. This study was to summarize the efficacy of SRT on lung metastasis. METHODS: A total of 39 patients with 62 lung metastatic lesions were treated by SRT in Cancer Center of Sun Yat-sen University. The median maximum diameter of the targets was 2.1 cm (1.2-4.9 cm), and the median maximum volume of the targets was 1.4 cm(3) (0.3-16.9 cm(3)). Of the 62 lesions, 21 were irradiated by single fraction with a dose of 20-24 Gy, and 41 were irradiated by 2-4 fractions with a dosage of 8-16 Gy/fraction and a total dose of 24-45 Gy. The median biologic effective dose (BED) of all lesions was 75 Gy (52.8-112.5 Gy). RESULTS: Response rate was 83.3% at 3 months after treatment. For the lesions with maximum diameter of < or =3 cm, the response rates were 62.5% for BED<75 Gy and 93.5% for BED> or =75 Gy (P=0.023). Median survival time was 21.6 months (3.4-62.2 months). The 1-year and 2-year overall survival rates, local control survival rates and progression-free survival rates were 78.9% and 48.2%, 88.4% and 82.8%, 65.0% and 39.3%, respectively. The 2-year overall survival rate was significantly higher in the subgroup with single lung metastatic lesion than in the subgroup with multiple lung metastatic lesions (57.7% vs. 30.0%, P=0.047), and significantly higher in the subgroup without metastasis in other organs than in the subgroup with metastasis in other organs (54.9% vs. 28.6%, P=0.003). The occurrence of radiation pneumonitis (> or =grade 2) was 5.1% (2/39). CONCLUSIONS: SRT is an effective and safe treatment for lung metastasis. The patients with single lung metastasis and without metastasis in other organs have better survival. BED> or =75 Gy has better local control effect on lung metastasis with maximum diameter of < or =3 cm.
Asunto(s)
Carcinoma de Células Escamosas/radioterapia , Neoplasias Pulmonares/radioterapia , Neoplasias Nasofaríngeas/patología , Radiocirugia/métodos , Adenocarcinoma/radioterapia , Adenocarcinoma/secundario , Adolescente , Adulto , Anciano , Carcinoma de Células Escamosas/secundario , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Hepáticas/patología , Neoplasias Pulmonares/secundario , Masculino , Persona de Mediana Edad , Neumonía/etiología , Radiocirugia/efectos adversos , Tasa de Supervivencia , Adulto JovenRESUMEN
BACKGROUND & OBJECTIVE: Surgery is the major treatment for glioma, and radiotherapy is often needed after operation. This study was to evaluate prognostic factors of patients with cerebral glioma treated with radiotherapy. METHODS: Records of 158 patients with cerebral glioma, including 123 patients with astrocytoma (AC), 12 patients with oligodendroglioma (OD) or mixed oligoastrocytoma (OA), and 23 patients with glioblastoma multiforme (GBM), received radiotherapy in our center were analyzed. Eighty patients received total resection, 77 received subtotal resection, and 1 received biopsy before radiotherapy. Median radiation dose was 58 Gy (36-75 Gy). Median waiting time from operation to radiotherapy was 29 days (12-261 days). Sixty-eight patients received chemotherapy before or after radiotherapy. Cox model was used for univariate and multivariate analysis. RESULTS: Median follow-up was 23 months (2-62 months), 27 patients relapsed, and 57 patients died. The 2- and 4-year overall survival rate were 66.5% and 45.7%. Univariate analysis showed that histologic grade (I/II vs. II/IV), histologic type (AC/OD vs. GBM), Karnofsky performance state (KPS) before radiotherapy (>/=80 vs.< 80), extent of resection (total vs non-total), and age(=40 years vs. >40 years) were significant predictors in association with overall survival rate of patients with glioma. Multivariate analysis showed that histologic grade (P=0.001), age (P=0.006), KPS before radiotherapy (P=0.009), and extent of resection (P=0.037) were independent prognostic factors of glioma. CONCLUSION: Low grade (I/II), age =40 years, KPS>/=80 before radiotherapy, and total resection are independent factors for predicting better survival of glioma patients.